Deal Watch: Shire, Allergan Move To Shore Up Core Franchises
Executive Summary
Bristol acquires Cardioxyl and its Phase II congestive heart failure candidate as the latest deal to firm up its specialty drug pipeline, while Sanofi inks a cancer immunotherapy deal with BioNTech and a pair of diabetes-related partnerships with Hanmi and Lexicon.
You may also be interested in...
Sanofi And Lexicon Fall Out Over Zynquista, As French Group Exits Diabetes Pact
Lexicon labelled Sanofi’s unilateral decision to exit their alliance ‘invalid’ and said the French drugmaker was thus ‘in breach of contract’. Sanofi said its move was triggered by Phase III trial data studying the dual SGLT1 and SGLT2 inhibitor in type-2 diabetes.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.